Support the Guardian

Fund independent journalism with £5 per month

Business Today
Business live
UK house prices rise in January, Novo Nordisk obesity drug sales surge – business live
Live  
UK house prices rise in January, Novo Nordisk obesity drug sales surge – business live
Nationwide says house prices rose 0.7%; the Danish maker of Ozempic and Wegovy predicts further strong growth in 2024
Headlines
Rail industry  
North of England faces travel disruption amid train drivers’ strike
North of England faces travel disruption amid train drivers’ strike
Tesla  
Elon Musk’s $56bn pay package is too much, judge rules
Alphabet  
Advertising slump sinks Google investor confidence despite overall high revenue
Microsoft  
Activision acquisition and bets on AI yield high quarterly revenue
UK economy  
IMF warns Jeremy Hunt against tax cuts in budget
Brexit  
New food checks likely to mean less choice, warn delis
Eurozone  
Recession narrowly avoided as German economy shrinks
Councils in crisis  
Ministers plan to push cash-strapped English councils to sell assets
Financial sector  
Labour vows to cut ‘red tape’ and ‘unashamedly champion’ UK sector
Telegraph takeover  
UK issues ‘stop meddling’ order to UAE-backed consortium
Sky  
Company to cut 1,000 jobs as customers move from pay-TV to internet
Oil  
Saudi Arabia surprises markets by ditching plan to raise production
Banking  
HSBC fined £57m over ‘serious’ deposit protection failings
Supermarkets  
Buying bigger packs may not get best deal, says watchdog
Today's agenda
House prices across the UK rose this month, as buyers took advantage of mortgage rates trending down, according to a survey.

The average price of a home increased by 0.7% to £257,656 in January, following no monthly change in December, according to Nationwide building society.

Compared with January last year, prices were down just 0.2%, following an annual decline of 1.8% in December. It was the smallest annual drop in a year.

Robert Gardner, Nationwide’s chief economist, said: "There have been some encouraging signs for potential buyers recently with mortgage rates continuing to trend down. This follows a shift in view amongst investors around the future path of Bank rate, with investors becoming more optimistic that the Bank of England will lower rates in the years ahead.

"These shifts are important as this led to a decline in the longer-term interest rates (swap rates) that underpin mortgage pricing around the turn of the year. However, the partial reversal in recent weeks in response to stronger than expected inflation and activity data cautions that the interest rate outlook remains highly uncertain.

"While a rapid rebound in activity or house prices in 2024 appears unlikely, the outlook is looking a little more positive. The most recent Rics survey suggests the decline in new buyer enquiries has halted, while there are tentative signs of a pick-up in the number of properties coming onto the market."

The Bank of England is expected to keep its base rate at 5.25% on Thursday but may lower some of its inflation forecasts, which could give it room to start cutting rates from the summer.

Denmark’s Novo Nordisk has reported strong revenue growth, with sales of its obesity and diabetes drugs soaring. Obesity drug sales alone jumped 154% at constant exchange rates to 41.6bn Danish kroner (£4.8bn) last year, fuelled by demand for Ozempic. Sales of diabetes drugs such as Wegovy and Saxenda grew by 52%. Obesity and diabetes sales together totalled 215bn kroner (nearly £25bn).

Overall sales rose 36% to 232bn kroner, while profit before tax jumped 52% to 104.7bn kroner.

The company has struggled to keep up with demand and is building more factories.

For 2024, sales growth is expected to be 18-26% at constant exchange rates, and operating profit growth is expected to be 21-29%.

Lars Fruergaard Jørgensen, president and chief executive, said: "We are very pleased with the strong performance in 2023 reflecting that more than 40 million people are now benefiting from our innovative diabetes and obesity treatments.

"Our focus in 2024 will be on reaching more patients, progressing and expanding our pipeline as well as the continued significant expansion of our production capacity."

Blockbuster anti-obesity drugs such as Ozempic appear to dampen inflammation – raising hope that they could be used to treat diseases, including Alzheimer’s and Parkinson’s, that are characterised by brain inflammation, according to the journal Nature.

Also coming up
• 7.45am GMT: France inflation for January (previous: 3.7%)
• 8.55am GMT: Germany unemployment for January (forecast: 11,000)
• 1pm GMT: Germany inflation for January (forecast: 3%, previous: 3.7%)
• 7pm GMT: US Federal Reserve interest rate decision (forecast: no change)
• 7.30pm GMT: Fed press conference

We’ll be tracking all the main events throughout the day ...
Opinion
Norway has made a vital climate leap. This is how Britain can do the same
Tessa Khan
Norway has made a vital climate leap. This is how Britain can do the same
Tories fret about a nanny state – but with decay all around, voters want politicians who step in
Rafael Behr
Media
Social media  
Taylor Swift AI images prompt US bill to tackle nonconsensual, sexual deepfakes
Taylor Swift AI images prompt US bill to tackle nonconsensual, sexual deepfakes
TikTok  
Universal Music Group threatens to pull song catalog from TikTok in furious open letter
Spotlight
‘We absolutely don’t welcome 20% rent increases’
Foxtons boss Guy Gittins  
‘We absolutely don’t welcome 20% rent increases’
The chief executive who cut his teeth in the estate agency’s sharp-suited, hard-pushing heyday worries today’s letting market is ‘terrible for tenants’
Popular on business
How UK’s new border controls will affect plants and animal imports
How UK’s new border controls will affect plants and animal imports
Buying bigger packs may not get best deal in UK supermarkets, says watchdog
Saudi Arabia surprises oil markets by ditching plan to increase production
Green economy must be next UK government’s No 1 priority – Lane Fox
IMF warns Hunt against tax cuts; eurozone avoids recession – as it happened
Get in touch
If you have any questions or comments about any of our newsletters please email newsletters@theguardian.com
 

… there is a good reason why people choose not to support the Guardian.

Not everyone can afford to pay for the news right now. That's why we choose to keep our coverage of Westminster and beyond, open for everyone to read. If this is you, please continue to read for free.

Over the past 13 years, our investigative journalism exposing the shortcomings of Tory rule – austerity, Brexit, partygate - has resulted in resignations, apologies and policy corrections. And with an election just round the corner, we won’t stop now. It’s crucial that we can all make informed decisions about who is best to lead the UK.

Here are three good reasons to choose to support us today.

1

Our quality, investigative journalism is a scrutinising force at a time when the rich and powerful are getting away with more and more.

2

We are independent and have no billionaire owner controlling what we do, so your money directly powers our reporting.

3

It doesn’t cost much, and takes less time than it took to read this message.

Choose to power the Guardian’s journalism for years to come, whether with a small sum or a larger one. If you can, make the choice to support us on a monthly basis from just £2. It takes less than a minute to set up, and you can rest assured that you’re making a big impact every single month in support of open, independent journalism. Thank you.

 
Manage your emails | Unsubscribe | Trouble viewing?
You are receiving this email because you are a subscriber to Business Today. Guardian News & Media Limited - a member of Guardian Media Group PLC. Registered Office: Kings Place, 90 York Way, London, N1 9GU. Registered in England No. 908396